Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
Public ClinicalTrials.gov record NCT01662986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge Study 2)
Study identification
- NCT ID
- NCT01662986
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 79 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2012 (Actual)
- Primary completion
- Apr 1, 2014 (Actual)
- Completion
- Apr 1, 2014 (Actual)
- Last update posted
- Oct 17, 2018
2012 – 2014
United States locations
- U.S. sites
- 50
- U.S. states
- 25
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.478.00243 Boehringer Ingelheim Investigational Site | Montgomery | Alabama | — | — |
| 205.478.00208 Boehringer Ingelheim Investigational Site | Flagstaff | Arizona | — | — |
| 205.478.00260 Boehringer Ingelheim Investigational Site | Glendale | Arizona | — | — |
| 205.478.00241 Boehringer Ingelheim Investigational Site | Loma Linda | California | — | — |
| 205.478.00240 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 205.478.00237 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 205.478.00231 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 205.478.00209 Boehringer Ingelheim Investigational Site | Danbury | Connecticut | — | — |
| 205.478.00250 Boehringer Ingelheim Investigational Site | Glastonbury | Connecticut | — | — |
| 205.478.00229 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 205.478.00200 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 205.478.00212 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 205.478.00265 Boehringer Ingelheim Investigational Site | Kissimmee | Florida | — | — |
| 205.478.00246 Boehringer Ingelheim Investigational Site | Lehigh Acres | Florida | — | — |
| 205.478.00248 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 205.478.00215 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 205.478.00261 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 205.478.00233 Boehringer Ingelheim Investigational Site | Vero Beach | Florida | — | — |
| 205.478.00236 Boehringer Ingelheim Investigational Site | Austell | Georgia | — | — |
| 205.478.00205 Boehringer Ingelheim Investigational Site | Lawrenceville | Georgia | — | — |
| 205.478.00225 Boehringer Ingelheim Investigational Site | Evanston | Illinois | — | — |
| 205.478.00264 Boehringer Ingelheim Investigational Site | Iowa City | Iowa | — | — |
| 205.478.00254 Boehringer Ingelheim Investigational Site | Olathe | Kansas | — | — |
| 205.478.00249 Boehringer Ingelheim Investigational Site | Topeka | Kansas | — | — |
| 205.478.00257 Boehringer Ingelheim Investigational Site | Hazard | Kentucky | — | — |
| 205.478.00234 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 205.478.00242 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 205.478.00258 Boehringer Ingelheim Investigational Site | Eunice | Louisiana | — | — |
| 205.478.00256 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 205.478.00210 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.478.00220 Boehringer Ingelheim Investigational Site | Towson | Maryland | — | — |
| 205.478.00204 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 205.478.00247 Boehringer Ingelheim Investigational Site | Winston Salem | Massachusetts | — | — |
| 205.478.00263 Boehringer Ingelheim Investigational Site | Rochester | Minnesota | — | — |
| 205.478.00201 Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| 205.478.00239 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 205.478.00227 Boehringer Ingelheim Investigational Site | Summit | New Jersey | — | — |
| 205.478.00253 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 205.478.00226 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 205.478.00232 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 205.478.00203 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 205.478.00206 Boehringer Ingelheim Investigational Site | Wyomissing | Pennsylvania | — | — |
| 205.478.00219 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 205.478.00222 Boehringer Ingelheim Investigational Site | Arlington | Texas | — | — |
| 205.478.00235 Boehringer Ingelheim Investigational Site | Kingwood | Texas | — | — |
| 205.478.00217 Boehringer Ingelheim Investigational Site | McKinney | Texas | — | — |
| 205.478.00216 Boehringer Ingelheim Investigational Site | Temple | Texas | — | — |
| 205.478.00230 Boehringer Ingelheim Investigational Site | Falls Church | Virginia | — | — |
| 205.478.00202 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 205.478.00224 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01662986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2018 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01662986 live on ClinicalTrials.gov.